Company / Operating Cash Flow per Share
Ultragenyx Pharmaceutical Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$5.04
FY2025
5-year range
-$6.77 / -$5.03
FY2021-FY2025
Trend
-0.2%
vs FY2024
Sector context
#198 of 212
Health Care
What the data says
Among 212 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 7% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-6.77 in FY2023 to $-1.15 in FY2016.
Based on SEC 10-K filings.
-5.04 in FY2025.
Improved from $-6.77 to $-5.04 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 212This company -$5.04 Sector average -$14.72
▼
+65.8% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 0.2% year-over-year.
- Ranks #198 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2016.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.04 | -0.2% |
| FY2024 | -$5.03 | +25.7% |
| FY2023 | -$6.77 | -23.3% |
| FY2022 | -$5.49 | -6.1% |
| FY2021 | -$5.17 | -2.9% |
| FY2020 | -$5.02 | -0.7% |
| FY2019 | -$4.99 | +24.1% |
| FY2018 | -$6.58 | -156.0% |
| FY2017 | -$2.57 | -123.9% |
| FY2016 | -$1.15 | +60.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026